Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

How Lilly Aims To Make Sure Good Drugs Don't Get Lost In Translation

Executive Summary

SVP/CSO Daniel Skovronsky says the company has invested in technology and biotech-like teams to speed up the process of translating targets identified in house into human data for novel drugs.

You may also be interested in...



Amgen’s Playing To Its R&D Strengths, Which No Longer Include Neuroscience

The company will focus on core therapeutics areas like oncology and cardiovascular disease, but left open the possibility of future work in neuroscience with a genetic basis for drug development.

Lift-Off For Lilly In Cancer Genetics With Loxo Buy

The New Year is just a week old but the biopharma merger and acquisitions merry-go-round is already spinning furiously as Lilly now steps in with a proposal to buy Loxo.

Lilly Ready For More Risk When It Comes To Early Deals

Chief Scientific Officer Dan Skovronsky has remit over business development at Eli Lilly, and he said the company is looking to do more deals, including higher-risk early stage molecules and new modalities, during an investor briefing in New York Dec. 19. The company also provided 2019 financial forecasts.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132281

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel